Amgen (NASDAQ:AMGN) issued an update on its FY18 earnings guidance on Tuesday morning. The company provided EPS guidance of $12.80-13.70 for the period, compared to the Thomson Reuters consensus EPS estimate of $13.47. The company issued revenue guidance of $21.9-22.8 billion, compared to the consensus revenue estimate of $22.71 billion.

AMGN stock traded down $2.72 during trading on Tuesday, reaching $171.94. 4,354,475 shares of the company traded hands, compared to its average volume of 4,796,622. The company has a debt-to-equity ratio of 1.35, a current ratio of 5.49 and a quick ratio of 5.17. The company has a market cap of $114,648.48, a P/E ratio of 13.67, a PEG ratio of 2.10 and a beta of 1.36. Amgen has a 12 month low of $152.16 and a 12 month high of $201.23.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing the Zacks’ consensus estimate of $3.03 by ($0.14). The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.84 billion. Amgen had a return on equity of 30.87% and a net margin of 8.66%. The company’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period last year, the firm earned $2.89 EPS. analysts anticipate that Amgen will post 13.28 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be given a $1.32 dividend. This represents a $5.28 dividend on an annualized basis and a dividend yield of 3.07%. The ex-dividend date is Wednesday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 41.97%.

Amgen announced that its Board of Directors has approved a stock buyback program on Thursday, February 1st that permits the company to buyback $10.00 billion in shares. This buyback authorization permits the medical research company to purchase shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its shares are undervalued.

A number of equities analysts have weighed in on AMGN shares. Vetr lowered Amgen from a buy rating to a hold rating and set a $184.25 price objective on the stock. in a research note on Wednesday, January 3rd. Royal Bank of Canada reiterated a hold rating and issued a $189.00 price objective on shares of Amgen in a report on Wednesday, January 24th. Barclays cut their price target on Amgen from $190.00 to $180.00 and set an equal weight rating on the stock in a report on Thursday, April 5th. ValuEngine downgraded Amgen from a buy rating to a hold rating in a report on Monday, April 2nd. Finally, Piper Jaffray reiterated a buy rating on shares of Amgen in a report on Tuesday, January 2nd. Two research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and ten have assigned a buy rating to the company. The stock has a consensus rating of Hold and an average price target of $190.57.

In related news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction on Friday, March 16th. The stock was sold at an average price of $189.75, for a total value of $289,368.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold 4,575 shares of company stock worth $818,330 in the last 90 days. Insiders own 0.27% of the company’s stock.

A number of institutional investors have recently modified their holdings of AMGN. FMR LLC lifted its stake in shares of Amgen by 4.8% during the second quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock worth $9,817,037,000 after purchasing an additional 2,587,041 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Amgen by 0.9% during the second quarter. Vanguard Group Inc. now owns 52,146,935 shares of the medical research company’s stock worth $8,981,266,000 after acquiring an additional 489,720 shares during the last quarter. Nordea Investment Management AB increased its position in shares of Amgen by 12.9% during the second quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock worth $1,212,602,000 after acquiring an additional 806,119 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Amgen by 3.1% during the second quarter. The Manufacturers Life Insurance Company now owns 3,968,892 shares of the medical research company’s stock worth $683,562,000 after acquiring an additional 121,202 shares during the last quarter. Finally, Janus Henderson Group PLC increased its position in shares of Amgen by 3,664.7% during the second quarter. Janus Henderson Group PLC now owns 3,699,351 shares of the medical research company’s stock worth $637,139,000 after acquiring an additional 3,601,087 shares during the last quarter. Hedge funds and other institutional investors own 85.76% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at https://www.dailypolitical.com/2018/04/24/amgen-amgn-issues-fy18-earnings-guidance.html.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Earnings History and Estimates for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.